Almac Receives Appreciation Award from OAPI
News Aug 02, 2013
In June 2013, Almac has hosted Otsuka America Pharmaceutical Inc.’s (OAPI) Clinical Trial Supply team at Almac’s North American Headquarters in Souderton, PA.
The highlight of the meeting was a presentation of an award to the Almac Clinical Services team by Brent Kelly, OAPI’s Director of Clinical Supply Operations.
Almac provided crucial clinical supply services for OAPI’s Abilify Maintena™ (aripiprazole) clinical trial program, supporting the approval of the once-monthly injectable treatment for schizophrenia earlier in 2013.
This recognizes Almac’s commitment to quality, customer service, and operational excellence.
Commenting on the award Celine Bradley, Almac’s Global VP of Operations said, “I am proud to receive this award from one of our valued customers, and I would like to congratulate OAPI on their successful registration of the Abilify Maintena product. Almac’s core values include our commitment to quality and customer focus, and it is very satisfying to have a client recognize when we have delivered on these. I would like to commend the Almac team for their dedication to successful and timely completion of this project. Awards like this highlight the importance of clinical trial supply in enabling our partners to make a real difference in patients’ lives.”
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE